Research programme: Lassa vaccines - Uvax Bio
Latest Information Update: 11 Mar 2024
At a glance
- Originator Uvax Bio
- Class Antivirals; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lassa fever
Most Recent Events
- 21 Dec 2023 Preclinical trials in Lassa fever in USA (Parenteral), prior to December 2023 (UVax Bio pipeline, December 2023)
- 20 Dec 2023 Uvax Bio holds the exclusive worldwide rights to the 1c-SApNP® platform and an expanding portfolio of 12 patented preclinical vaccine candidates, prior to December 2023 (UVax Bio pipeline, December 2023)